Drug Landscape ›
APIXABAN ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 28,054
Most-reported reactions
Atrial Fibrillation — 3,991 reports (14.23%) Dyspnoea — 3,632 reports (12.95%) Cerebrovascular Accident — 3,527 reports (12.57%) Thrombosis — 2,812 reports (10.02%) Off Label Use — 2,695 reports (9.61%) Cardiac Disorder — 2,509 reports (8.94%) Death — 2,355 reports (8.39%) Fall — 2,326 reports (8.29%) Fatigue — 2,207 reports (7.87%) Anaemia — 2,000 reports (7.13%)
Source database →
APIXABAN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is APIXABAN approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for APIXABAN in United States?
Marketing authorisation holder not available in our data.